Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society of Gene and Cell Therapy (ASGCT 2025) 28th Annual Meeting taking place May 13-17, 2025 in New Orleans, LA.
The abstracts being presented at ASGCT 2025 capture the outcome of efforts to advance Tenaya's core capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of adeno-associated virus (AAV) gene therapies.
Abstract highlights
: Building on previous research that showed the superior cardiomyocyte-targeting and robust transduction attributes of AAV serotype 9 (AAV9) compared to other naturally occurring capsids, Tenaya's researchers combined high throughput in vivo experimental screening with multiple in silico screening tools to efficiently identify various novel capsid candidates. Novel capsids were then compared to one another and to AAV9 in murine and non-human primate models. Select top performing capsids were further evaluated and found to outperform AAV9 in terms of cardiomyocyte targeting and efficient in vivo cardiac gene therapy.
Tenaya researchers will share efforts to develop prime editing, a precision gene editing technique, aimed at cardiomyocytes. The machinery required for prime editing exceed the capacity of a single AAV capsid, so Tenaya researchers created a prototype utilizing one of the company's engineered AAV capsids, a dual cassette arrangement delivered via two AAV capsids, and cardiomyocyte-specific regulatory elements. The therapeutic potential of this prime editing prototype was studied in an RBM20 murine model of DCM. The prime editing prototype successfully achieved correction of the mutated RBM20 allele, improving cardiac function and reversing disease in the mouse model. A humanized mouse model of RBM20-mutant DCM was also developed and validated by Tenaya researchers. Testing of the prototype in this model demonstrated effective cardiac editing of the humanized allele using the in vivo dual vector prime editing approach.
: Tenaya previously presented research on the development of a Cas9 gene editing therapy, TN-501, designed to specifically inactivate the mutant phospholamban (PLN)-R14del allele, and thereby eliminate the "poison peptide" effects of the mutant protein while preserving wild-type function. Preclinical studies in murine models demonstrated that a low dose of a murine surrogate of TN-501 effectively prevented mutant PLN protein aggregation, reduced cardiac fibrosis, improved cardiac function, and significantly enhanced survival to wild-type levels. Doses tested were well tolerated and anti-Cas9 antibody responses and Cas9 T-cell activation were low.
Tenaya successfully established Sf9/rBV-based manufacturing processes at the 1000L scale for its clinical-stage AAV gene therapy programs and subsequently also established a proprietary HEK293-based manufacturing process. Tenaya's HEK393 process utilizes a single plasmid expression system, as well novel transfection reagents, to improve overall yield while lowering overall costs compared to current commercially available options, which may support the development of more cost-effective AAV gene therapies.
Details of Tenaya's ASGCT 2025 presentations are as follows:
Tuesday, May 13, 2025Poster Abstract Session - 6:00 pm – 7:30 pm
Abstract: #523Title: A Humanized RBM20 Mouse Model Exhibits Dilated Cardiomyopathy Phenotypes and Enables Development of In Vivo Prime Editing for Treating Human RBM20 Cardiomyopathy PatientsPresenting author: Wenjing Liang, Ph.D., Scientist
Abstract: #952Title: High Productivity HEK293 AAV Production Platform Enabled by Novel Transfection Reagents and Proprietary Plasmid Expression SystemsPresenting author: Charles Feathers, Senior Manager, Process Development
Wednesday, May 14, 2025Poster Abstract Session – 5:30 pm – 7:30 pm
Abstract: #1022Title: TN-501 Gene Editing Therapy for PLN-R14del-Associated CardiomyopathyPresenting author: Huanyu Zhou, Ph.D., Associate Director
Abstract: #1028Title: Developing In Vivo Prime Editing as a Potential Treatment Option for Heart DiseasePresenting author: Lindsey Rollosson, Research Associate II
Abstract: #1396 Title: Engineering Novel AAV Capsids for Cardiac Gene DeliveryPresenting author: Ze Cheng, Ph.D., Principal Scientist
Following the conference, Tenaya's presentations will be available in the 'Our Science' section of the company's website.
About Tenaya TherapeuticsTenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com.
Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as 'will,' 'potential,' 'may,' and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, the presentation of data covering Tenaya's capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of AAV gene therapies; the therapeutic potential of Tenaya's prime editing technology in a humanized RBM20 murine model of DCM; TN-501 as a potential treatment for PLN R14del-associated DCM; the commercial potential of Tenaya's manufacturing process to support the development of more cost-effective AAV gene therapies. The forward-looking statements contained herein are based upon Tenaya's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: availability of data at the referenced times; risks associated with the process of discovering, developing and commercializing therapies that are safe and effective for use as human therapeutics; Tenaya's ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for any of its product candidates; Tenaya's continuing compliance with applicable legal and regulatory requirements; Tenaya's ability to raise any additional funding it will need to continue to pursue its business and product development plans; Tenaya's reliance on third parties; Tenaya's manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya's ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact Michelle CorralVP, Corporate Communications and Investor RelationsTenaya TherapeuticsIR@TenayaThera.com
InvestorsAnneMarie FieldsStern IR AnneMarie.Fields@SternIR.com
MediaWendy RyanTen Bridge Communicationswendy@tenbridgecommunications.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Erectile Dysfunction Devices Market Set to Surge at a CAGR of ~8% by 2032 with Rising Global Demand and Technological Advancements
The demand for erectile dysfunction devices is largely fueled by the growing incidence of ED, especially among men with chronic health conditions like cardiovascular disease, diabetes, and hypertension. While ED can affect men across all age groups, it is more commonly seen in older adults who often have associated health concerns such as prostate cancer, anxiety, and depression. Furthermore, the expanding elderly male population, combined with higher rates of obesity and sedentary behaviors like smoking and physical inactivity, are significant contributor to the market's expansion. New York, USA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erectile Dysfunction Devices Market Set to Surge at a CAGR of ~8% by 2032 with Rising Global Demand and Technological Advancements | DelveInsight The demand for erectile dysfunction devices is largely fueled by the growing incidence of ED, especially among men with chronic health conditions like cardiovascular disease, diabetes, and hypertension. While ED can affect men across all age groups, it is more commonly seen in older adults who often have associated health concerns such as prostate cancer, anxiety, and depression. Furthermore, the expanding elderly male population, combined with higher rates of obesity and sedentary behaviors like smoking and physical inactivity, are significant contributor to the market's expansion. DelveInsight's Erectile Dysfunction Devices Market Insights report provides the current and forecast market analysis, individual leading erectile dysfunction devices companies' market shares, challenges, erectile dysfunction devices market drivers, barriers, trends, and key erectile dysfunction devices companies such as Coloplast Group, Zimmer Aesthetics, Augusta Medical Systems, Medispec, MTS Medical, Boston Scientific Corporation, NOVAmedtek, Promedon GmbH, and others in the market. Erectile Dysfunction Devices Overview Erectile dysfunction devices play a crucial role in the management of erectile dysfunction, a condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. These devices are particularly valuable for men who cannot take or do not respond to oral pharmacological treatments. Common types of ED devices include vacuum erection devices (VEDs), penile implants (inflatable or malleable), and constriction rings. VEDs work by creating a vacuum around the penis to draw blood into it, while penile implants offer a more permanent solution through surgically inserted devices that mimic the natural erection process. These options provide men with greater control over their sexual function and can significantly improve the quality of life and Dysfunction Devices Regional Market Insights North America dominated the erectile dysfunction devices market in 2024, owing to several critical factors. This leadership is primarily driven by the increasing incidence of erectile dysfunction and rising awareness about the condition among the regional population. Contributing to this trend is the growing number of individuals affected by prostate cancer, hypertension, and diabetes—key risk factors for erectile dysfunction. Additionally, major industry players in the region are prioritizing technological progress and product development. For instance, in January 2025, Comphya SA, an innovative medtech company, received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials for CaverSTIM, the first implantable neuromodulator designed to treat erectile dysfunction. These advancements are expected to drive significant growth in the market by providing new treatment options for affected individuals. As a result, the convergence of rising erectile dysfunction cases, a high burden of contributing health conditions, and ongoing innovation in device technology is projected to fuel substantial market growth in North America between 2025 and 2032. To know more about why North America is leading the market growth in the erectile dysfunction devices market, get a snapshot of the Erectile Dysfunction Devices Market Outlook Recent Developments in the Erectile Dysfunction Devices Market In January 2025, Comphya SA, a pioneering medical technology company, announced that the FDA granted Investigational Device Exemption (IDE) approval to initiate clinical trials for CaverSTIM, the first implantable neuromodulator developed to treat erectile dysfunction. In June 2024, Ohh-Med Medical Ltd. launched VerticaPlus with a cloud-based mobile app. Vertica is a pioneering medical device designed to enhance erection quality over time by targeting the Tunica Albuginea in the penis, thereby reducing leakage and outflow. This innovative approach optimizes the natural erectile mechanism without relying on medication, allowing for complete spontaneity in intimate relations and eliminating associated side effects. To read more about the latest highlights related to the erectile dysfunction devices market, get a snapshot of the key highlights entailed in the Erectile Dysfunction Devices Key Players in the Erectile Dysfunction Devices Market The erectile dysfunction devices market is driven by several key players that focus on technological innovation, product development, and strategic partnerships to expand their market share. Prominent companies such as Coloplast Group, Zimmer Aesthetics, Augusta Medical Systems, Medispec, MTS Medical, Boston Scientific Corporation, NOVAmedtek, Promedon GmbH, Global Life Technologies LLC, Zephyr Surgical Implants, Owen Mumford, Vacurect, T.E. Inc., SILIMED, STORZ MEDICAL AG, Rigicon, Inc., TIMM Medical, Alma Lasers, Comphya SA, Ohh-Med Medical Ltd., and others are at the forefront of the industry. These firms offer a range of medical devices, including vacuum erection devices (VEDs), penile implants, and constriction rings, catering to diverse patient needs. Their emphasis on clinically effective solutions, robust research and development pipelines, and global distribution networks has positioned them as leaders in the growing erectile dysfunction devices market. Which MedTech key players in the erectile dysfunction devices market are set to emerge as the trendsetter explore @ Top Erectile Dysfunction Devices Companies Erectile Dysfunction Devices Market Key Factor Analysis Erectile Dysfunction Devices Market Drivers The erectile dysfunction devices market is primarily driven by the growing prevalence of erectile dysfunction worldwide. This rise is closely linked to an increase in the number of risk factors, such as diabetes, cardiovascular diseases, obesity, and lifestyle-related conditions that contribute to the onset of erectile dysfunction. Additionally, the expanding geriatric male population, which is more susceptible to such conditions due to age-related physiological changes, is further propelling the demand for effective treatment solutions, including medical devices designed to manage erectile dysfunction. Erectile Dysfunction Devices Market Restraints and Challenges One of the major restraints in the erectile dysfunction devices market is the high cost of advanced devices, which limits accessibility for a large segment of the patient population, particularly in developing regions. Additionally, the complexity of these devices and the potential risk of malfunction pose significant challenges, often leading to patient hesitation and reduced adoption rates. These factors collectively hinder the widespread use and acceptance of erectile dysfunction devices despite their clinical benefits. Erectile Dysfunction Devices Market Opportunities The erectile dysfunction devices market presents significant growth opportunities driven by the integration of advanced technologies, such as robotic implantation and other innovative approaches. These advancements are enhancing the precision, safety, and effectiveness of erectile dysfunction treatments, leading to improved patient outcomes and satisfaction. As healthcare systems increasingly adopt minimally invasive and tech-enabled solutions, the demand for technologically sophisticated erectile dysfunction devices is expected to rise, creating a favorable environment for market expansion. Get a sneak peek at the erectile dysfunction devices market dynamics @ Global Erectile Dysfunction Devices Market Report Report Metrics Details Coverage Global Study Period 2022–2032 Erectile Dysfunction Devices Market CAGR ~8% Erectile Dysfunction Devices Market Size by 2032 USD 3 Billion Key Erectile Dysfunction Devices Companies Coloplast Group, Zimmer Aesthetics, Augusta Medical Systems, Medispec, MTS Medical, Boston Scientific Corporation, NOVAmedtek, Promedon GmbH, Global Life Technologies LLC, Zephyr Surgical Implants, Owen Mumford, Vacurect, T.E. Inc., SILIMED, STORZ MEDICAL AG, Rigicon, Inc., TIMM Medical, Alma Lasers, Comphya SA, Ohh-Med Medical Ltd., and others Erectile Dysfunction Devices Market Assessment Erectile Dysfunction Devices Market Segmentation Erectile Dysfunction Devices Market Segmentation By Product: Penile Implants, Shockwave Therapy Devices, Vacuum Therapy Devices, and Others Erectile Dysfunction Devices Market Segmentation By Approach: Invasive and Non-Invasive Erectile Dysfunction Devices Market Segmentation By End User: Hospitals & Clinics, Ambulatory Surgical Centers, and Others Erectile Dysfunction Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Interested in knowing the erectile dysfunction devices market by 2032? Click to get a snapshot of the Erectile Dysfunction Devices Market Analysis Table of Contents 1 Erectile Dysfunction Devices Market Report Introduction 2 Erectile Dysfunction Devices Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Erectile Dysfunction Devices Market Key Factors Analysis 6 Erectile Dysfunction Devices Market Porter's Five Forces Analysis 7 Erectile Dysfunction Devices Market Layout 8 Erectile Dysfunction Devices Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Related Reports Erectile Dysfunction Market Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key erectile dysfunction companies, including Vigonvita Life Sciences, Futura Medical Developments, Initiator Pharma, Pharmicell Co., Ltd., BioIntegrate, Biozeus Biopharmaceutical, Can-Fite Biopharma, Fabre-Kramer Pharmaceuticals, Humanetics Pharmaceuticals, Hemostemix Inc., Ilgen Bio, Aquestive Therapeutics, MicroCures, Dicot AB, CURE Pharmaceutical, IX BIOPHARMA, Exopharm, Oncotelic Therapeutics, Blue Cell Therapeutics, S1 Biopharma, among others. Erectile Dysfunction Pipeline Erectile Dysfunction Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key erectile dysfunction companies, including Vigonvita Life Sciences, Futura Medical Developments, Initiator Pharma, Pharmicell Co., Ltd., BioIntegrate, Biozeus Biopharmaceutical, Can-Fite Biopharma, Fabre-Kramer Pharmaceuticals, Humanetics Pharmaceuticals, Hemostemix Inc., Ilgen Bio, Aquestive Therapeutics, MicroCures, Dicot AB, CURE Pharmaceutical, IX BIOPHARMA, Exopharm, Oncotelic Therapeutics, Blue Cell Therapeutics, S1 Biopharma, among others. Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others. Prostate Cancer Pipeline Prostate Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prostate cancer companies, including Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, among others. Prostate Cancer Diagnostics Market Prostate Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer diagnostics companies, including F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott., MDx Health, Siemens Healthcare, OPKO Health, Inc., Genomic Health, Inc., Agilent Technologies, Inc., BD., BIOCEPT, INC., Proteomedix, A3P Biomedical AB, GE HealthCare., Soteria Medical BV, Bio-Techne., Indica Labs, Inc., miR Scientific, MINOMIC®, ACON Laboratories, Inc., Hologic, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
38 minutes ago
- Business Upturn
Pumpkin is Back! The Human Bean Brews Up Fall Favorites Starting August 11
By GlobeNewswire Published on August 12, 2025, 23:13 IST Medford, OR, Aug. 12, 2025 (GLOBE NEWSWIRE) — Summer's last sips are giving way to autumn's first flavors as pumpkin returns to The Human Bean menus starting August 11. This year's collection features four pumpkin-inspired beverages designed to capture the coziness of the season — from the first crisp mornings to the last golden leaves. Whether the moment calls for warm comfort or cool spice, these pumpkin-flavored specialties promise to kick off the unofficial start of fall. Pumpkin Snowy makes its seasonal return with rich espresso, creamy white chocolate and pumpkin, topped with whipped cream and a dusting of cinnamon sprinkles. Available hot, iced or as a granita. Pumpkin Java Chip stirs up fall fun with blended Java Chip, pumpkin drizzle, and a generous whipped cream topper. It's a perfect sweet treat to bring back that fall feeling! Pumpkin Granita is blended to perfection with espresso and rich pumpkin flavor, then finished with a swirl of pumpkin sauce around the cup. It's a chilly match for warm late-summer afternoons. Pumpkin Patch brings together iced matcha with a dreamy layer of Pumpkin Cold Foam — rich,creamy, and spiced just right. 'Fall represents more than a seasonal menu change—it's about nostalgia and celebrating traditions that bring people together,' said Janie Page, chief marketing officer at The Human Bean. 'Our pumpkin collection pairs with life's seasonal adventures, and there's something for everyone with this year's lineup.' Pumpkin specials and toppers, like Pumpkin Cold Foam and Cinnamon Sprinkles, are available while supplies last. More information and a drive-thru locator are available at ______ About The Human Bean With a passion for creating happy 'Human Beans', the company's drive-thrus around the U.S. have established a reputation for friendly baristas, high-quality coffee and innovative flavors. The Human Bean opened its first drive-thru espresso stand in Ashland, Oregon in 1998, and currently supports over 260 locations open or under development in 23 states. Learn more at Attachment Pumpkin is Back! The Human Bean Brews Up Fall Favorites Starting August 11 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
38 minutes ago
- Business Upturn
Global Ship Recycling Market to Reach $13 Billion by End of 2030
By GlobeNewswire Published on August 12, 2025, 23:36 IST Boston, Aug. 12, 2025 (GLOBE NEWSWIRE) — According to the latest study from BCC Research, the 'Global Ship Recycling Market' is estimated to increase from $9.1 billion in 2025 to $13 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.4% from 2025 through 2030. The report presents a comprehensive analysis of the global ship recycling market, combining quantitative and qualitative insights to highlight the latest trends and developments. It evaluates market performance in terms of revenue, measured in millions of dollars. The market is segmented by vessel type, including bulk carriers, container ships, oil tankers, general cargo ships, and others. It also categorizes vessels by size: below 60,000 DWT, between 60,000 DWT and 125,000 DWT, and above 125,000 DWT. Additionally, the report examines ship recycling methods such as beaching, dry-docking, alongside/pier-breaking, and other emerging techniques. This report is especially relevant today due to the imminent enforcement of the Hong Kong International Convention for the Safe and Environmentally Sound Recycling of Ships. Although adopted in 2009, the convention officially came into force on June 26, 2025, introducing stricter global standards for ship recycling. Its primary objective is to ensure that ships, at the end of their operational life, are dismantled in a manner that minimizes risks to human health, safety, and the environment. This regulatory shift is expected to significantly impact industry practices, making timely insights and analysis crucial for stakeholders. The factors driving the market's growth include: Increasing Demand for Scrap Steel: Scrap steel recovered from dismantled ships is a valuable resource for steel production, especially in countries with growing infrastructure needs. It offers a cost-effective and environmentally friendly alternative to producing new steel, driving demand for ship recycling. Increasing Age of the Global Shipping Fleet: Many ships in operation are nearing or have exceeded their optimal service life, making them inefficient and costly to maintain. As older vessels are phased out, they enter the recycling stream, providing a steady supply for the industry. Stringent Ship End-of-Life Regulations: International and regional regulations now require ships to be dismantled in safe, environmentally sound facilities. These rules promote responsible recycling practices, increasing demand for certified shipbreaking yards and boosting market growth. Request a sample copy of the global market for ship recycling report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $7 billion Market size forecast $13 billion Growth rate CAGR of 7.4% for the forecast period of 2025-2030 Segments covered Vessel Type, Vessel Size, Methods Countries covered Bangladesh, India, Pakistan, Turkey, Rest of the World Market drivers Increasing Demand for Scrap Steel Increasing Age of the Global Shipping Fleet Stringent Ship End-of-Life Regulations Interesting facts: In 2024, the three major vessel types of general cargo ships, bulk carriers and container ships accounted for 60% of the market share. Bangladesh, India and Pakistan holds more than 90% market share in the global ship recycling market. Breaking down a 40,000 ton ship can take about three months for 50 workers. Emerging startups: Wreckdock Vessel Recycling: The company offers sustainable solutions for end-of-life maritime assets. Its new recycling facility in Saudi Arabia is designed to provide clean, safe, and equitable practices for the dismantling and recycling of ships and offshore assets. Elegant Exit Co.: The company is involved in ship recycling innovation, advancing financial strategies and industrial processes. The company's plan includes owning and operating these vessels until their planned recycling date. The report addresses the following questions: What are the projected size and growth rate of the market? The global ship recycling market was valued at $7 billion in 2024 and will reach $13 billion by 2030. The CAGR is 7.4% for the forecast period 2025-2030. Which factors are driving the growth of the market? Increasing demand for scrap steel. Increasing age of the global shipping fleet. Stringent ship end-of-life regulations. What are the major challenges and restraints in the market? Limited availability of vessels. Growth of global trade. Health hazards in irresponsible ship recycling. Which market segments are covered in the report? The ship recycling market is segmented on the basis of vessel type, vessel size and methods. The vessel type segment is further segmented into bulk carriers, container ships, oil tankers, general cargo ships and others. The vessel size segment is sub-segmented into below 60,000 DWT, 60,000 DWT to 125,000 DWT and above 125,000 DWT. The method segment is sub-segmented into beaching, dry-docking, alongside/pier-breaking and others. Which method segment will be dominant through 2030? The beaching method will be dominant in this segment. Which country has the largest market share? Bangladesh has the largest market share; the market is gaining interest mainly due to the high prices offered by recyclers from the region and the less stringent regulation imposed to handle ship breaking. Market leaders include: ALANG SOSIYA SHIP RECYCLING YARD DORTEL GEMI SOKUM EMR USA HOLDINGS INC. KSRM STEEL PLANT LTD. LEELA WORLDWIDE GROUP LEYAL GEMI SOKUM MARINE METALS MRC PORT COLBORNE OSM THOME PRIYA BLUE INDUSTRIES R.L. KALTHIA SHIP BREAKING PVT. LTD. SALASAR BALAJI SHIP BREAKERS PVT. LTD. SPOT SHIPPING A.S. VMS INDUSTRIES LTD. WIRANA Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact [email protected]. About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email [email protected] or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
